Cinclus Pharma

Cinclus Pharma develops small molecules for the treatment of gastric acid related diseases. GERD is a digestive disorder causing retrograde flow of gastric juice into the esophagus. This leads to erosions, acid regurgitations and heartburn. Cinclus Pharma was founded by pioneers in GERD treatment, both with extensive experience from Astra and AstraZeneca, where clinical phase I and phase II studies were performed on the product candidate linaprazan. Together with the team at Cinclus Pharma the founders are now taking the development of linaprazan glurate to the next level. Cinclus Pharmas lead drug candidate, linaprazan glurate, represents a novel class of drugs; Potassium Competitive Acid Blocker (P-CAB). A P-CAB is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs. Linaprazan glurate is firstly being developed for treatment of Gastroesophageal reflux disease (GERD), clinical studies are ongoing. Linaprazan glurate has the potential to ...